COCP Cocrystal Pharma Inc.

2.7
+0.05  (+2%)
Previous Close 2.65
Open 2.66
Price To Book 0.73
Market Cap 80792305
Shares 29,923,076
Volume 8,493
Short Ratio
Av. Daily Volume 48,905

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a initial data released January 22, 2019. SVR12 66%.
CC-31244
Hepatitis C
Phase 1 trial to be initiated 1H 2019.
CC-42344
Influenza

Latest News

  1. Cocrystal Pharma Provides Update on Clinical Development Program Evaluating CC-31244 for Ultra-Short Treatment of Hepatitis C Virus
  2. Robbins Arroyo LLP: Shareholder Lawsuit Says Cocrystal Pharma, Inc. (COCP) Misled Shareholders
  3. Cocrystal Announces Board Changes
  4. 4 Pharma Stocks Raising Eyebrows (1/3/19)
  5. UPDATE: Cocrystal Pharma to work with Merck on flu therapy, sending shares up 32% premarket
  6. Cocrystal Pharma Announces Exclusive Worldwide License and Collaboration Agreement with Merck
  7. Cocrystal Pharma Announces Presentation at the RespiDART 2018: Frontiers in Drug Development Against Respiratory Viruses Conference
  8. WeissLaw LLP: Cocrystal Pharma, Inc. is the Subject of a Legal Investigation
  9. DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Cocrystal Pharma, Inc. (Formerly BioZone Pharmaceuticals, Inc.) and Encourages Investors with Losses of $100,000 to Contact the Firm
  10. FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Cocrystal Pharma, Inc. f/k/a/ BioZone Pharmaceuticals, Inc. (COCP) and Lead Plaintiff Deadline – November 19, 2018
  11. CLASS ACTION UPDATE for COCP, JT and DY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  12. DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Cocrystal Pharma, Inc. (Formerly BioZone Pharmaceuticals, Inc.) and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm
  13. DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Cocrystal Pharma, Inc. f/k/a/ BioZone Pharmaceuticals, Inc. (COCP) and Lead Plaintiff Deadline - November 19, 2018
  14. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cocrystal Pharma, Inc. f/k/a BioZone - COCP
  15. FINAL DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Cocrystal Pharma, Inc. (Formerly BioZone Pharmaceuticals, Inc.) and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm